Clinical Trial Update: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing samatasvir in combination with simeprevir and/or TMC647055/ritonavir (with or without ribavirin) for 12 weeks in chronic hepatitis C inf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ribavirin (ribavirin)
• Ritonavir (Ritonavir)
• Samatasvir (samatasvir)
• Simeprevir (simeprevir)
• TMC647055

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C Virus | Phase 2 | Status: COMPLETED